Description

Simple

A medication used to treat asthma, allergic reactions in the nose, and some skin conditions.

Clinical

A corticosteroid used to treat asthma, allergic rhinitis, nasal congestion, nasal polyps, dermatitis, and pruritus.

Overview

Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][10,11]. It has a glucocorticoid receptor binding affinity 22 times stronger than [dexamethasone] and higher than many other corticosteroids as well[2]. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][10,11].

Pharmacology

Indication

There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients ≥4 years[FDA Label]. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years, treating symptoms of nasal congestion from... Read more

Pharmacodynamic

Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of [dexamethasone][ Read more

Mechanism of action

In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes[ Read more

Absorption

The mean time to peak concentration is 1.0 to 2.5 hours[FDA Label]. Bioavailability has been reported as Read more

Protein binding

98% to 99% (in vitro concentration of 5 to 500ng/mL)[FDA Label][10].

Volume of distribution

Steady state volume of distribution of 152L[FDA Label].

Clearance

The clearance rate of mometasone furoate is not readily available[1], though it may be close to 90L/h[ Read more

Half life

The terminal half life of an inhaled dose is approximately 5 hours[FDA Label] though it has been reported as 5.8 hours by other sources[10, Read more

Route of elimination

For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine[FDA Label][10].

Toxicity

Overdose with a mometasone furoate inhaler may occur with chronic overuse[FDA Label][10]. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require... Read more

Adverse Effects

Contraindications

  • Route:
    • Respiratory (inhalation)
  • Dose Form:
    • Powder, metered
  • Sex Group: all
  • Regions: US
  • Patient Conditions:
      • Name: Acute asthma episodes
      • Drugbank Id: DBCOND0108126
  • Route:
    • Respiratory (inhalation)
  • Dose Form:
    • Powder, metered
  • Sex Group: all
  • Regions: US
  • Patient Conditions:
      • Name: Status Asthmaticus
      • Drugbank Id: DBCOND0001831
  • Route:
    • Nasal
    • Respiratory (inhalation)
    • Topical
  • Dose Form:
    • Ointment
    • Powder, metered
    • Spray
  • Hypersensitivity:
    • true
  • Sex Group: all
  • Regions: US

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Mometasone furoate
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
Mometasone furoate may increase the anticoagulant activities of (R)-warfarin.
(S)-Warfarin
Mometasone furoate may increase the anticoagulant activities of (S)-Warfarin.
1-Testosterone
The risk or severity of edema formation can be increased when 1-Testosterone is combined with Mometasone furoate.
1,10-Phenanthroline
The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Mometasone furoate.
16-Bromoepiandrosterone
The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Mometasone furoate.
19-norandrostenedione
The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Mometasone furoate.
1alpha-Hydroxyvitamin D5
The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Mometasone furoate.
1alpha,24S-Dihydroxyvitamin D2
The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Mometasone furoate.
2-Methoxyethanol
The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Mometasone furoate.
2,4-thiazolidinedione
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with 2,4-thiazolidinedione.
4-hydroxycoumarin
Mometasone furoate may increase the anticoagulant activities of 4-hydroxycoumarin.
4-Hydroxytestosterone
The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Mometasone furoate.
5-androstenedione
The risk or severity of edema formation can be increased when 5-androstenedione is combined with Mometasone furoate.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Mometasone furoate.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be increased when combined with Mometasone furoate.
Abatacept
The risk or severity of adverse effects can be increased when Abatacept is combined with Mometasone furoate.
Abediterol
The risk or severity of hypokalemia can be increased when Mometasone furoate is combined with Abediterol.
Abetimus
The risk or severity of adverse effects can be increased when Abetimus is combined with Mometasone furoate.
Acarbose
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Acarbose.
Aceclofenac
The risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Aceclofenac.
11 References
  1. 1 . Szefler SJ: Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S26-31.PubMed: 11449203
  2. 2 . Hubner M, Hochhaus G, Derendorf H: Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005 Aug;25(3):469-88. doi: 10.1016/j.iac.2005.05.004.PubMed: 16054538
  3. 3 . Crim C, Pierre LN, Daley-Yates PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001 Sep;23(9):1339-54.PubMed: 11589253
  4. 4 . Teng XW, Cutler DJ, Davies NM: Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos. 2003 Nov;24(8):321-33. doi: 10.1002/bdd.362.PubMed: 14595701
  5. 5 . FDA Approved Drug Products: Asmanex Mometasone Furoate Inhalation Powder Link
  6. 6 . FDA Approved Drug Products: Nasonex Mometasone Furoate Nasal Spray Link
  7. 7 . FDA Approved Drug Products: Elocon Mometasone Furoate Lotion Link
  8. 8 . FDA Approved Drug Products: Sinuva Mometasone Furoate Sinus Implant Link
  9. 9 . FDA Approved Drug Products: Elocon Mometasone Furoate Ointment Link
  10. 10 . Mometasone Furoate Nasonex FDA Label File
  11. 11 . Mometasone Furoate Elocon FDA Label File